Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 8
Submit an article Journal homepage
645
Views
33
CrossRef citations to date
0
Altmetric
Author's View

Immunological consequences of selective BRAF inhibitors in malignant melanoma

Neutralization of myeloid-derived suppressor cells

Bastian Schilling Department of Dermatology; University Hospital; University Duisburg-Essen; Essen, GermanyCorrespondence[email protected]
&
Annette Paschen Department of Dermatology; University Hospital; University Duisburg-Essen; Essen, Germany
Article: e25218 | Received 23 May 2013, Accepted 29 May 2013, Published online: 10 Jun 2013

References

  • Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175 - 208; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090733; PMID: 16551247
  • Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319 - 26; http://dx.doi.org/10.1016/j.semcancer.2012.02.003; PMID: 22349515
  • Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546 - 53; http://dx.doi.org/10.1200/JCO.2006.08.5829; PMID: 17577033
  • Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Görgens A, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; In press http://dx.doi.org/10.1002/ijc.28168; PMID: 23526263
  • Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol 2013; 14:280 - 92; http://dx.doi.org/10.1007/s11864-013-0226-8; PMID: 23420410
  • Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203:1651 - 6; http://dx.doi.org/10.1084/jem.20051848; PMID: 16801397
  • Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185:2273 - 84; http://dx.doi.org/10.4049/jimmunol.1000901; PMID: 20644162
  • Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479; PMID: 22156613
  • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118; PMID: 20551059
  • Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365 - 6; http://dx.doi.org/10.1056/NEJMc1302338; PMID: 23550685

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.